Quantinno Capital Management LP Sells 3,339 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Quantinno Capital Management LP cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,417 shares of the company's stock after selling 3,339 shares during the period. Quantinno Capital Management LP's holdings in IDEXX Laboratories were worth $4,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Sax Wealth Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after purchasing an additional 617 shares during the last quarter. Hantz Financial Services Inc. raised its stake in IDEXX Laboratories by 11.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock valued at $3,199,000 after buying an additional 800 shares in the last quarter. Paragon Capital Management Inc. lifted its position in IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after acquiring an additional 782 shares during the last quarter. Manitou Investment Management Ltd. boosted its stake in IDEXX Laboratories by 491.0% during the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock worth $21,582,000 after purchasing an additional 43,369 shares during the period. Finally, Fiera Capital Corp lifted its stake in shares of IDEXX Laboratories by 12.3% in the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock worth $58,377,000 after acquiring an additional 15,463 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IDXX. Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Finally, Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $536.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded down $4.52 during mid-day trading on Tuesday, hitting $517.16. 606,894 shares of the stock traded hands, compared to its average volume of 649,204. The company has a market cap of $41.59 billion, a PE ratio of 48.47, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.60. The firm has a 50 day simple moving average of $435.69 and a two-hundred day simple moving average of $432.77. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the prior year, the company posted $2.71 earnings per share. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.